Study Details
CAP-1002: A Study Drug for Human Allogeneic Cardioshere-Derived Cells for People with Duchenne Muscular Dystrophy (DMD)
(IRB#: IRB_00150933)
Duchenne Muscular Dystrophy (DMD) is a disease that weakens people's muscles over time. CAP-1002 is a study drug to help people with this disease. Research is needed to learn the safety and effectiveness of the drug. This information we gain may aid future patients.
- Male Only
- Over 7 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: Male Only
Age: Over 7 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 10 years and older
- Duchenne Muscular Dystrophy (DMD) diagnosis
- Taking medication such as prednisone for at least 12 months, and must have stable health for at least 6 months
- Receiving care at a credible multidisciplinary DMD center
- In-person at the University of Utah
Exclusion Criteria
- Already received other specific treatments at 3, 6, or 12 months
- History or current drug or alcohol abuse
- Use metformin or insulin within 3 months before participation
- Severe illness 30 days before participation
- Planned surgery 6 months during participation
Will I be paid for my time?
Yes
IRB#: IRB_00150933
PI: Russell Butterfield
Department: PEDIATRIC NEUROLOGY
Approval Date: 2022-09-15 06:00:00
Study Categories: Brain Health Studies
Specialties: Neurology